Trial reportFrontiers in pharmacology2025
Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.
Trial report in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Y-shape branched PEGylated recombinant human growth hormone (YPEG-rhGH) is a suitable drug for the treatment of growth hormone deficiency. The aim of this study was to establish a population pharmacokinetics/pharmacodynamics (PopPK/PD) model of YPEG-rhGH in the elderly. The safety and tolerability of the drug were investigated, and the possibility of flexible dosing regimen was explored. A total of 16 healthy elderly subjects and 36 healthy adults participated in the PopPK analysis. Only elderly subjects were included in the PopPK/PD analysis. After subcutaneous injection of the drug, serum samples were collected to analyze the time course of YPEG-rhGH concentrations and insulin-like growth factor-1 (IGF-1) levels. Additionally, the safety and tolerability of the investigational drug were evaluated. Results show that the pharmacokinetics of serum YPEG-rhGH after subcutaneous injection can be better described by a two-compartment model with first-order absorption and nonlinear elimination. The indirect response model (IDR) demonstrated good predictive capability for the relative baseline ratio of IGF-1 levels in elderly subjects following YPEG-rhGH administration. The magnitude of the increase in the relative baseline ratio of IGF-1 decreased with increasing weight, and increasing age marginally reduced the increase in the baseline ratio of YPEG-rhGH-increased IGF-1 in elderly people, but the effect decreased with increasing dosing intervals. All reported adverse reactions were mild. In the final model, AGE was identified as a significant covariate for K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.